AI model may predict who can skip surgery for rectal cancer

NCT ID NCT06364371

Recruiting now Knowledge-focused Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study is developing a model that combines MRI scans, blood tests, and tissue samples to predict whether rectal cancer patients achieve a complete response after neoadjuvant therapy. Researchers will enroll 106 patients with locally advanced rectal cancer and collect data before, during, and after treatment. The goal is to improve selection for a watch-and-wait approach, potentially sparing some patients from surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this model could help doctors identify which rectal cancer patients can safely avoid surgery after neoadjuvant therapy, improving quality of life.
What could go wrong: This is an early observational study with only 106 participants, so the model may not be accurate enough for widespread use. It is not a treatment trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pathologic Complete Response rectal cancer rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATHOLOGIC COMPLETE RESPONSE PREDICTIVE CANCER MODEL

Contacts and locations

Locations

The Sixth Affiliated Hospital, Sun Yatsen University
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.